Page 11 - Interim Analysis News Today

This JAMA Guide to Statistics and Methods describes why interim analyses are performed during group sequential trials, provides examples of the limitations of i

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Tonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) has undergone a transformation over the past year as it has built up a robust pipeline of clinical stage assets focused on the treatment of central nervous system (CNS) and immunological diseases. In addition, the company’s balance sheet has never been stronger. As of March 31, 2021, Tonix had approximately $164.2...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral...

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Message : Required fields PONTE VEDRA, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced positive interim results from the ALIGN3D™ clinical study in a podium presentation at the ongoing American College of Foot and Ank...

Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021 Clostridioides difficile Infection With and Without Sepsis Presenting Author: Alpesh Amin, MD, MBA, Thomas Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California Irvine EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET DDW has made abstracts available o...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos ... BIOPHYTIS SAMay 12, 2021 GMT This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-...

Share: nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("BIOPHYTIS" or the "Company"), a clinical-stage biotechnology company focused ...

Message : Required fields PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering ...

Published: Apr 29, 2021 Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suf...